Viewing Study NCT04534205

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 3:27 AM
Ignite Modification Date: 2026-02-03 @ 6:44 AM
Study NCT ID: NCT04534205
Status: RECRUITING
Last Update Posted: 2025-12-10
First Post: 2020-08-27
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1
Sponsor: BioNTech SE
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Unresectable Head and Neck Squamous Cell Carcinoma View
None Metastatic Head and Neck Cancer View
None Recurrent Head and Neck Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Cancer vaccine View
None RNA vaccine View
None HNSCC View
None BNT113 View
None Pembrolizumab View
None HPV16 View
None Metastatic View
None Unresectable View
None Recurrent View
None Head and neck View
None mRNA vaccine View
None HPV-positive View
None Head and neck cancer View